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Editorial Comment 
The Amiodarone Odyssey* 
KOONLAWEE NADEMANEE, MD, FACC 
Denver, Colorado 
A paradoxic agent. Amiodarone-that pharmacologic 
enigma-has been seeking its place as a cardiovascular 
therapeutic agent for >20 years. First developed by Labaz 
Laboratory in Belgium as an antianginal compound, it was 
later found to possess antiarrhythmic and electrophysiologic 
properties (I). It is a puzzling compound, whose pharmaco-
dynamics and pharmacokinetics are poorly understood to 
this day (2,3). Not just a simple class III agent, amiodarone 
has many properties: sodium channel blocking, calcium 
channel blocking, nonspecific sympathetic blocking (3). 
The drug exerts effects on thyroid metabolism (4) and acts 
as a phospholipase enzyme inhibitor (5); the latter action 
may play a significant role in maintaining lipid cell mem-
branes during ischemia. Amiodarone inhibits adenosine 
triphosphate-sensitive potassium channel activity (6), which 
may be a factor in modulating arrhythmogenesis during 
ischemia. In essence, amiodarone possesses anti-ischemic, 
antiarrhythmic and antifibrillatory properties. These actions 
have a delayed onset that, coupled with the drug's long 
elimination half-life (1,2,7), makes it difficult to titrate the 
optimal dose for individual patients and may also be the 
reason for its sustained effect. Given these multiple and 
complex pharmacologic behaviors, it is not surprising that 
there has been quite a disparity in the reports of the rates of 
efficacy and toxicity of amiodarone (7-10. The drug's poorly 
understood pharmacology and its reputed toxicity have 
made us reluctant to use it except as a last resort. 
Nevertheless, most cardiologists believed that amio-
darone was worth using in patients with refractory ventric-
ular tachycardia and ventricular fibrillation (7-10. The belief 
that amiodarone helped those patients when aU other stan-
dard therapy had failed was recognized by the Food and 
Drug Administration which, prompted by the reality that 
large numbers of physicians were prescribing the drug on a 
compassionate basis, took the unprecedented action of ap-
proving the drug even though it had bypassed the established 
governmental regulatory process of drug approval. 
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The present study. The study of amiodarone by Cere-
muzynski et al. (12) in this issue of the Journal appears in the 
midst of our struggle with the paradox that the same drug can 
be at once so helpful and so toxic. These investigators 
compared amiodarone with placebo in postmyocardial in-
farction patients who did not necessarily have high density 
ventricular arrhythmias. Theirs is the first trial to convinc-
ingly show that an antiarrhythmic agent-amiodarone-
reduces the incidence of cardiac death in postmyocardial 
infarction patients by reducing the incidence of sudden 
cardiac death. Like most secondary prevention trials (13,14) 
(trials of beta-blocking agents or angiotensin-converting en-
zyme inhibitors), it included all survivors of myocardial 
infarction except those who had contraindications to beta-
blockers. Most deaths in this study were of cardiac origin (all 
33 deaths in the placebo group and 19 of the 21 deaths in the 
amiodarone group). A significant number of these deaths 
were sudden (within 1 h of the onset of symptoms): 20 in 
placebo-treated and 10 in amiodarone-treated patients. How-
ever, in contrast to findings in the beta-blocker trials, amio-
darone did not prevent reinfarction in this study: 14 
and 10 patients, respectively, developed reinfarction in the 
amiodarone and placebo groups. It is thus likely that amio-
darone reduces the incidence of sudden cardiac death by 
primary mechanisms such as antifibriIIatory and anti-
arrhythmic properties rather than by lowering the inci-
dence of ischemia-related ventricular fibrillation episodes 
because of the drug's favorable effect on the number of 
ischemic events. 
Amiodarone caused remarkably few short-term side ef-
fects. At first glance, the incidence of side effects leading to 
discontinuation oftreatment is quite modest. Fifty-five of the 
305 amiodarone-treated patients were withdrawn from ther-
apy when they developed "adverse" effects, as opposed to 
19 of the 308 placebo-treated patients. But a closer reading of 
the data shows that most of the patients could have contin-
ued treatment with the drug because some of the side effects 
that led to drug discontinuation were inconsequential. The 
11 patients who developed benign first-degree atrioventric-
ular block and were withdrawn from treatment could have 
continued receiving amiodarone, as could have some of 
the 14 patients who developed bradycardia if the cutoff 
range had been altered from a heart rate of 50 beats/min to 
>45 beats/min, which is a safe threshold. Patients who 
developed right or left bundle branch block or QT interval 
prolongation also could have continued to receive amio-
darone because these. side effects were negligible. And 
many of those with abnormal thyroid function test results 
(which actually reflected expected changes in thyroid func-
tion induced by amiodarone) had no clinical signs and 
symptoms of hyperthyroidism or hypothyroidism; as the 
authors themselves point out, these patients could have 
continued to receive the drug. Thus, the number of serious 
side effects would decrease from 55 to approximately 25 in 
the total study group of 305 patients, a proportion much 
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closer to that in the placebo group. Both results are an 
emphatic indication that amiodarone is very well tolerated in 
the short term. 
The authors also cautiously interpret the findings on the 
effect of amiodarone on reducing the mortality rate. Of the 
20 patients in the amiodarone-treated group who died, 10 
died after they stopped taking the drug. Although the authors 
are justified in counting these as amiodarone-related deaths 
on the basis of the intention-to-treat principle, these circum-
stances may indicate that amiodarone is even more effective 
than is reported in this study. 
These data show that amiodarone prevents cardiac death 
and sudden cardiac death in postmyocardial infarction pa-
tients. What makes this trial quite exceptional is that the 
investigators designed this to be a pilot study to be followed 
by a larger definitive trial. As it turned out, the present study 
yielded definitive findings. A critical examination of the 
preceding criteria for drug discontinuation and death rate 
yields an even more strongly positive evaluation of amio-
darone. The results of the present study together with the 
results of Burkart et al. (15) and preliminary data from 
ongoing studies force us to ask the following questions. 
Mechanism of amiodarone benefit.· Why does amiodarone 
appear to benefit postmyocardial infarction patients when 
other class I drugs (phenytoin, mexiletine, aprindine, encain-
ide, ftecainide, moricizine) fail (16-18)? Although propo-
nents of class III agents may infer from these data that 
amiodarone works by prolonging repolarization, the infer-
ence that all class III agents have the same effect as 
amiodarone is too simplistic because we still don't under-
stand how amiodarone works. For example (bearing in mind 
that both amiodarone and sotalol have both class II and class 
III properties), the trial of sotalol reported by Julian et al. 
(19) did not show that sotalol reduced mortality, although 
there was a trend suggesting that possibility (the mortality 
rate was 18% lower in the sotalol than in the placebo group). 
Specifically, sotalol did not prevent sudden cardiac death, 
which had a rate of 2.9% in the sotalol group compared with 
2.4% in the placebo group. Sotalol significantly reduced the 
incidence of myocardial infarction in the study of Julian et al. 
(19). This observation is interesting because if prolongation 
of the action potential duration is the principal mechanism of 
action in preventing sudden cardiac death in postmyocardial 
infarction patients, one would have expected sotalol to be as 
effective as amiodarone in the study of Julian et al. But it 
wasn't and, therefore, it cannot be solely the class III effect 
that accounts for the success of amiodarone. Having said 
this, one cannot rule out the possibility that the class III 
action plays a role in preventing sudden cardiac death. It 
may be that sotalol has more proarrhythmic effects that 
cause fatal arrhythmias, thus offsetting the drug's beneficial 
effects. Unlike sotalol, amiodarone has negligible proar-
rhythmic effects (3,7,8), perhaps because its calcium channel 
blocking properties may prevent early afterdepolarization 
induced by abnormal repolarization; this mechanism is be-
lieved to cause torsade de pointes and polymorphic ventric-
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ular tachycardia in patients with abnormal prolongation of 
repolarization (20). Thus, amiodarone may be effective be-
cause of, rather than despite, its pharmacologic complexity. 
Ongoing and future research. Knowing what these data 
tell us about amiodarone, would it now be ethical to conduct 
additional large studies randomizing postmyocardial infarc-
tion patients to placebo and amiodarone to confirm the 
results of the present study as Ceremuzynski et al. suggest? 
Should we now treat all survivors of myocardial infarction 
with amiodarone because of our present knowledge that 
amiodarone saves lives? Before answering these questions, 
we should await the results of three ongoing major trials: the 
Canadian Amiodarone Myocardial Infarction Arrhythmia 
Trial (CAMIAT), the European Myocardial Infarction Ami-
odarone Trial (EMIAT), and the Veterans Administration 
Cooperative Study Comparing Amiodarone vs. Placebo in 
Heart Failure Patients with Malignant Ventricular Arrhyth-
mias. These studies will confirm or deny the results of the 
present study and should address the most serious concern 
about amiodarone: whether its benefits will continue over 
the long term and whether they will outweigh the risk of 
serious side effects that are likely to develop, the most 
worrisome of these being pulmonary fibrosis. 
Other studies are needed to determine whether amio-
darone would have greater benefit by itself or in combination 
with other therapy (angiotensin-converting enzyme inhibi-
tors, aspirin, beta-blockers, for example). It is crucial as well 
that we test the drug in those patients who are at very high 
risk for sudden cardiac death (that is, patients who have a 
low ejection fraction and a high density premature ventric-
ular complex rate) and randomize them to either amiodarone 
or beta-blockers. Throughout all of this ongoing research, 
we must bear in mind that the results of the present study 
apply only to short-term amiodarone therapy; when patients 
receive amiodarone for longer periods of time, they will 
develop side effects. Other clinical considerations will prob-
ably arise in studies of amiodarone administered over longer 
periods of time. For instance, long-term amiodarone therapy 
adversely affects lipid metabolism (21). In addition, it is not 
known whether amiodarone-induced high cholesterol levels 
will cause accelerated atherosclerosis in patients with coro-
nary artery disease (similar to the present study patients). 
Although new data clearly show that amiodarone is more 
effective and less toxic than had been thought, and although 
other clinical trials are needed, this research will not answer 
our questions about amiodarone's puzzling pharmacology. 
We still do not understand how amiodarone operates at the 
molecular and cellular level. Research on how this drug 
works will give insight into the mechanisms of sudden 
cardiac death and ways to prevent it: it is time for us to 
embark on that odyssey. 
I thank Mary Kolb. BA for editorial assistance. 
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